Icovamenib Achieves a Mean Reduction in HbA1c Greater than 1% at Week 26 Following 4 Weeks of Dosing in Type...
INX-315, a potential best-in-class CDK2 inhibitor, to be evaluated in combination with Verzenio® (abemaciclib) and fulvestrant Combination therapy to be...
Promotes Edward Brennan, MD, FACS to Chief Scientific Officer & Head of R&D ProgramTORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE...
Phase 2 CLOVER-WaM pivotal study data selected for oral presentation at 66th Annual American Society of Hematology Meeting and Exposition...
HCW Biologics entered into License, Research and Co-Development Agreement with WY Biotech for one of its new proprietary preclinical molecules...
OPUVIZ™ is one of the first wave aflibercept biosimilars in EuropeOPUVIZ is the second European Commission (EC)-approved ophthalmology biosimilar under...
The Company will now target five major cancer types with its four clinically active compounds across both TCR-T cell therapies...
-- Four Pediatric patients treated in French early-access program achieved meaningful weight reduction at three months on setmelanotide therapy --...
NMD Pharma Initiates Phase 2 Study of NMD670 in Patients with Charcot-Marie-Tooth Disease Type 1 and 2 Aarhus, Denmark, 18...
Treatment with nomlabofusp modified gene expression and lipid profiles in addition to increasing frataxin (FXN) levels in study participants with...
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 18, 2024) - Earlier in November 2024, Medexus Pharmaceuticals (TSX: MDP) (OTCQX:...
New report analyses Mainland China's transformation into a global biopharma powerhouse, with key insights for international stakeholders LONDON, Nov. 18,...
LONDON, UNITED KINGDOM / ACCESSWIRE / November 18, 2024 / Nanomerics Ltd., a private speciality pharmaceutical company announced that it...
CHICAGO, Nov. 16, 2024 (GLOBE NEWSWIRE) -- In August of 2023, the Foundation for Sarcoidosis Research (FSR) submitted a Request...
Consistently rapid, deep and durable reduction in serum TTR accompanied by evidence of disease stabilization or improvement after a one-time...
Two New Analyses from SEQUOIA-HCM Demonstrate Treatment with Aficamten Improves Post-Exercise Oxygen Uptake Recovery and Quality of Life New Data...
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data from post-hoc...
SHANGHAI, Nov. 16, 2024 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading...
NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the...
WOODCLIFF LAKE, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq and OTCMKTS: EGRX) (the “Company” or “Eagle”)...